Latham & Watkins Advises the Underwriters in Design Therapeutics’ Initial Public Offering

A life sciences-focused capital markets team represents the underwriters in the biotechnology company’s offering.

March 26, 2021

Design Therapeutics, Inc., a biotechnology company developing a platform of gene targeted chimera (GeneTAC™) small molecules for the treatment of serious degenerative disorders caused by inherited nucleotide repeat expansions, announced the pricing of its initial public offering of 12,000,000 shares of its common stock at a price to the public of US$20 per share.

Latham & Watkins LLP represents the underwriters in the offering with a capital markets team led by Bay Area partner Brian Cuneo, Orange County partner Drew Capurro, and San Diego partner Matt Bush, with Orange County associate Mekbeb Hagos. Advice as also provided on benefits and compensation matters by Bay Area partner James Metz, with Bay Area associate Nathaniel Hsieh; on intellectual property matters by Bay Area partner Chris Hazuka, with San Diego associate Robert Yeh and New York associate David Suh; on regulatory matters by Washington, D.C. partner Elizabeth Richards, Bay Area counsel Betty Pang and Heather Deixler, with Washington, D.C. associate Julie Choi Shin; and on tax matters by Bay Area partner Grace Lee, with Orange County associate Janet Hsu.

Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.